Cogent Biosciences Inc (NAS:COGT)
$ 9.79 -2.08 (-17.52%) Market Cap: 1.07 Bil Enterprise Value: 1.07 Bil PE Ratio: 0 PB Ratio: 4.13 GF Score: 33/100

Q1 2019 Unum Therapeutics Inc Earnings Call Transcript

May 13, 2019 / 12:00PM GMT
Release Date Price: $12.84 (-6.41%)
Operator

Good day, ladies and gentlemen, and welcome to the Unum Therapeutics First Quarter 2019 Results Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to turn the conference over to Stephanie Ascher. Ma'am, you may begin.

Stephanie Baritz Ascher
Stern Investor Relations, Inc. - SVP

Good morning and welcome to the Unum Therapeutics quarterly investor conference call. Today, we'll be sharing updates on our company's progress and our financial results for the first quarter ended March 31, 2019. With me on our call today are Chuck Wilson, Chief Executive Officer; Michael Vasconcelles, Chief Medical Officer; Seth Ettenberg, Chief Scientific Officer; and John Green, Vice President of Finance. Following our prepared remarks, we'll open the line for questions.

Before we begin, I need to remind you that estimates and other forward-looking statements included in this call represent the company's view as of today, May 13, 2019. Unum Therapeutics disclaims any obligation to update these

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot